Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 119

Sort by

Sort Order Select

Journal Articles

Open-Label Phase 1 Study to Evaluate the Safety of SGN-35T in Patients with Relapsed/Refractory CD30-Expressing Lymphoid Malignancies (SGN35T-001; trial in progress)

Tatyana Feldman, Hun Ju Lee, Gizelle Popradi, Graham P. Collins, Daniel Morillo, Ming Jin Yan, Tara Chen, Youn H. Kim

Blood (2024) 144 (Supplement 1): 6356.

https://doi.org/10.1182/blood-2024-200265

Published: 2024

Journal Articles

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Jasmine Zain, Swaminathan P Iyer, Enrica Marchi, Mitul Gandhi, Youn H. Kim, Michael S. Khodadoust, Jonathan E. Brammer, Christina Poh, Pierluigi Porcu, Kimberley Dilley, Matthias Will, Andrea Kantor, Cathrine Leonowens, Nenad Tomasevic, H. Miles Prince, Steven Horwitz

Blood (2024) 144 (Supplement 1): 980.

https://doi.org/10.1182/blood-2024-206053

Published: 2024

Journal Articles

Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma

Leyla Bojanini, Melba Herrera, Shufeng Li, Tarek Bandali, Nicole Y. Xu, Abdullah A. Ahmed, Michael S. Khodadoust, Youn H. Kim

Blood (2024) 144 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2024-198783

Published: 2024

Journal Articles

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Blood (2024) 144 (Supplement 1): 3056.

https://doi.org/10.1182/blood-2024-200596

Published: 2024

Journal Articles

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2024-200587

Published: 2024

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Blood (2024) 144 (Supplement 1): 466.

https://doi.org/10.1182/blood-2024-194796

Published: 2024

Journal Articles

Genetic alteration of class I HLA in cutaneous T-cell lymphoma

Alexa C Kwang, George E Duran, Sebastian Fernandez-Pol, Safa Najidh, Shufeng Li, Armando N Bastidas Torres, Erica B Wang, Melba Herrera, Tarek I Bandali, David M Kurtz, Youn H Kim, Michael S Khodadoust

Blood blood.2024024817.

https://doi.org/10.1182/blood.2024024817

Published: 2024

Includes: Supplemental data

Journal Articles

Retrospective Study to Evaluate Probability of MR4 Maintenance Following Frontline Nilotinib Dose De-Escalation after MR4 Achievement in the Patients with Chronic Myeloid Leukemia in Chronic Phase

Eshrak Al-Shaibani, Maria Agustina Perusini, Josephine Anne Lucero, Gopila Gupta, May Chiu, Filza Gul, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 6386.

https://doi.org/10.1182/blood-2023-187689

Published: 2023

Journal Articles

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 6035.

https://doi.org/10.1182/blood-2023-180499

Published: 2023

Journal Articles

Outcomes of Allogeneic HSCT in Elderly Patients (70 years old and above) -a Canadian Experience

Yomna Eissa, Eshrak Al-Shaibani, Carol Chen, Shiyi Chen, Igor Novitzky-Basso, Arjun D. Law, Wilson Lam, Fotios Michelis, Auro Viswabandya, Armin Gerbitz, Ivan Pasic, Dennis D. H. Kim, Jeffrey H. Lipton, Jonas Mattsson, Rajat Kumar

Blood (2023) 142 (Supplement 1): 3733.

https://doi.org/10.1182/blood-2023-181118

Published: 2023

Journal Articles

Clinical, Cytogenetic and Immunophenotypic Spectra of Post-Transplant Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

Elizabeth Kathryn Herrity, Tommy Alfaro, Mariana Pinto Pereira, Igor Novitzky-Basso, Wilson Lam, Ivan Pasic, Fotios Michelis, Arjun D. Law, Auro Viswabandya, Adam Smith, Anne Maria Tierens, Armin Gerbitz, Rajat Kumar, Jonas Mattsson, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 2206.

https://doi.org/10.1182/blood-2023-187145

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: A Post Hoc Analysis Examining Disease Burden and Patient Characteristics from the Phase 3 Mavoric Trial in Mycosis Fungoides and Sézary Syndrome

Michi M Shinohara, Youn H. Kim, Kevin Molloy, Pietro Quaglino, Julia Scarisbrick, Susan R. Thornton, Kerry Sandilands, Jen E Liu, Annabel Nixon, Angela Williams, Pablo L. Ortiz-Romero

Blood (2023) 142 (Supplement 1): 1704.

https://doi.org/10.1182/blood-2023-188808

Published: 2023

Journal Articles

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability

Blood (2023) 142 (Supplement 1): 1702.

https://doi.org/10.1182/blood-2023-184898

Published: 2023

Journal Articles

Real World Experience of FLT3-Inhibitor Post-Transplant Maintenance with Sorafenib Demonstrating Superior Overall- and Relapse Free Survival Following Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD Mutated Acute Myeloid Leukemia

Yomna Eissa, Eshrak Al-Shaibani, Igor Novitzky-Basso, Ivan Pasic, Wilson Lam, Jose-Mario Capo-chichi, Arjun D. Law, Fotios Michelis, Auro Viswabandya, Armin Gerbitz, Rajat Kumar, Jonas Mattsson, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 3589.

https://doi.org/10.1182/blood-2023-185951

Published: 2023

Journal Articles

Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or Imatinib

Ho-Jae Han, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W. Deininger, Jong-Won Kim, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 6337.

https://doi.org/10.1182/blood-2023-188135

Published: 2023

Journal Articles

DNA Methylation Instability: A Novel Biomarker for Aging, Clonality, and Cancer

Salman Basrai, Robert Kridel, Mehran Bakhtiari, Dennis D. H. Kim, Fernando L. Scolari, Filio Billia, Andrea Arruda, Mark D. Minden, Sagi Abelson

Blood (2023) 142 (Supplement 1): 4059.

https://doi.org/10.1182/blood-2023-173489

Published: 2023

Journal Articles

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Blood (2023) 142 (Supplement 1): 185.

https://doi.org/10.1182/blood-2023-173806

Published: 2023

Journal Articles

Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2023-190775

Published: 2023

Journal Articles

In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid Leukemia

Ho-Jae Han, Eun-Ju Park, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W. Deininger, Jong-Won Kim, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 6336.

https://doi.org/10.1182/blood-2023-185440

Published: 2023

Journal Articles

Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome

Michael S. Khodadoust, Eric Mou, Youn H. Kim

Blood (2023) 141 (7): 695–703.

https://doi.org/10.1182/blood.2020008241

Published: 2023

NARROW

Open-Label Phase 1 Study to Evaluate the Safety of SGN-35T in Patients with Relapsed/Refractory CD30-Expressing Lymphoid Malignancies (SGN35T-001; trial in progress)

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Genetic alteration of class I HLA in cutaneous T-cell lymphoma

Retrospective Study to Evaluate Probability of MR4 Maintenance Following Frontline Nilotinib Dose De-Escalation after MR4 Achievement in the Patients with Chronic Myeloid Leukemia in Chronic Phase

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

Outcomes of Allogeneic HSCT in Elderly Patients (70 years old and above) -a Canadian Experience

Clinical, Cytogenetic and Immunophenotypic Spectra of Post-Transplant Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: A Post Hoc Analysis Examining Disease Burden and Patient Characteristics from the Phase 3 Mavoric Trial in Mycosis Fungoides and Sézary Syndrome

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability

Real World Experience of FLT3-Inhibitor Post-Transplant Maintenance with Sorafenib Demonstrating Superior Overall- and Relapse Free Survival Following Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD Mutated Acute Myeloid Leukemia

Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or Imatinib

DNA Methylation Instability: A Novel Biomarker for Aging, Clonality, and Cancer

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma

In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid Leukemia

Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only